Reduced Intensity Allogeneic Stem Cell Transplantation With Matched Unrelated Donors for Patients With Hematologic Malignancies.

Trial Profile

Reduced Intensity Allogeneic Stem Cell Transplantation With Matched Unrelated Donors for Patients With Hematologic Malignancies.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 01 May 2014

At a glance

  • Drugs Alemtuzumab (Primary) ; Busulfan; Cyclophosphamide; Fludarabine; Methotrexate; Rituximab; Tacrolimus
  • Indications Acute lymphoblastic leukaemia; Acute myeloid leukaemia; B cell lymphoma; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Chronic myelomonocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Graft-versus-host disease; Hodgkin's disease; Mantle-cell lymphoma; Myelodysplastic syndromes; Myeloproliferative disorders; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 10 Jul 2012 Actual end date (Mar 2012) added as reported by ClinicalTrials.gov.
    • 30 Mar 2012 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top